Reproterol

Source: Wikipedia, the free encyclopedia.
Reproterol
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Inhalation (MDI), IV
ATC code
Legal status
Legal status
  • DE: § 48 AMG/§ 1 MPAV (Prescription only)
Identifiers
  • (RS)-7-(3-{[2-(3,5-dihydroxyphenyl)-2-hydroxyethyl]amino}propyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione
JSmol)
  • CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CCCNCC(C3=CC(=CC(=C3)O)O)O
  • InChI=1S/C18H23N5O5/c1-21-16-15(17(27)22(2)18(21)28)23(10-20-16)5-3-4-19-9-14(26)11-6-12(24)8-13(25)7-11/h6-8,10,14,19,24-26H,3-5,9H2,1-2H3 ☒N
  • Key:WVLAAKXASPCBGT-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Reproterol is a short-acting[1] β2 adrenoreceptor agonist used in the treatment of asthma.[2]

It was patented in 1965 and came into medical use in 1977.[3]

Stereochemistry

Reproterol contains a stereocenter and is

racemate, an equal mixture of the two enantiomers.[4]

Enantiomers of reproterol

(R)-Reproterol
CAS number: 210710-33-1
(S)-Reproterol
CAS number: 210710-34-2

References

  1. S2CID 10032756
    .
  2. S2CID 203732706
    .
  3. ISBN 9783527607495
    .
  4. ISBN 978-3-946057-10-9
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Reproterol&oldid=1180986621"